RPRX 26.43 Stock Price Royalty Pharma plc
Range: | 25.1001-31.655 | Vol Avg: | 2191173 | Last Div: | 1.04 | Changes: | 0.33 |
Beta: | 0.47 | Cap: | 15.14B | Currency: | USD | Exchange: | NASDAQ |
Sector: | Healthcare | IPO: | Tue Jun 16 2020 | Empoloyees: | 75 |
CUSIP: | G7709Q104 | CIK: | 0001802768 | ISIN: | GB00BMVP7Y09 | Country: | US |
CEO: | Mr. Pablo Gerardo Legorreta | Website: | https://www.royaltypharma.com |
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.